Matinas BioPharma

Matinas BioPharma is an American biopharmaceutical company based in Bedminster, New Jersey.

On January 10, 2019, Matinas announced it had entered an agreement with an undisclosed pharmaceutical company to “evaluate synergistic effects of Matinas’ lipid-nano-crystal (“LNC”) platform delivery technology with their partner’s nucleic acid polymer technology.”¹⁾ CEO Jerome Jabbour said that the collaboration would “provide solutions for companies developing innovative nucleic acid polymers, small molecule drugs, vaccines, proteins and potentially even gene-editing technologies.”

In November 2020, Matinas received a $3.75 million award from the Cystic Fibrosis Foundation.²⁾

In December 2020, Matinas announced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate oral formulations of Gilead Sciences’s antiviral drug remdesivir in its potential treatment against COVID-19.

On April 11, 2022, Matinas and BioNTech announced a research collaboration “to evaluate a novel delivery technology for mRNA-based vaccines.”³⁾

In January 2023, Matinas and National Resilience “entered into a Material Transfer and Evaluation Agreement focused on exploring the potential for oral delivery of identified nucleic acids.”⁴⁾ In early 2023, the company sought funding from the Biomedical Advanced Research and Development Authority (BARDA), and continued into its third project with Genentech.

Gilead Sciences announced it had ended its partnership with Matinas in January 2023 in order to pursue their own remdesivir “pro-drug”.⁵⁾

Matinas is running clinical trials for MAT2203, a cryptococcal meningitis treatment, led by principal investigators David Boulware and David Meya.⁶⁾

SternAegis invested in Matinas in May 2013.⁹⁾

• Website
• White Rose Wiki